Coverage starts with the reason for treatment.

Ordinary Medicare drug coverage has a use rule

Medicare calls its prescription-drug benefit Part D.

Its ordinary benefit continued to exclude medicines for weight loss on September 26, 2026.

A different accepted medical use, including treatment for type 2 diabetes, may qualify a prescription for Part D payment. Another example is lowering the chance of a heart attack or stroke for adults with existing disease of the heart or blood vessels who also have obesity or overweight. Ask the prescriber which approved use fits your condition.

The plan’s own medicine list and approval requirements still decide whether it will pay.

A temporary programme is a separate route

GLP-1 drugs mimic a signal the body makes naturally to help regulate blood sugar and hunger. Semaglutide and tirzepatide are examples.

Eligible people could get certain medicines through the Medicare GLP-1 Bridge for a monthly copay of $50 on September 26, 2026.

The part of the bill paid by a patient is called a copay.

July 1, 2026, is the programme’s start date; its end date is December 31, 2027. For 2026, advance approvals and pharmacy payments are handled by one central service. Your usual Part D drug plan’s payment system does not handle them. Ask the prescriber and pharmacy about using the Bridge.

This is a temporary programme with its own conditions. Ordinary Part D still excludes medicine prescribed for weight loss.

Ask the prescriber to check eligibility

The minimum age is 18 under rules checked September 26, 2026. The weight and health conditions are judged from when GLP-1 treatment began. They use a number called BMI to compare your weight and height. Ask the prescriber to check your BMI and the conditions below.

One way to qualify is a BMI of 35 or more.

With a BMI of 30 or more, one of three conditions is required. The first is heart failure with preserved ejection fraction, a specific type of heart failure. The second is chronic kidney disease at stage 3a or higher.

The third is blood pressure that stays too high despite two blood-pressure medicines. Here, either reading can qualify: the top must be above 140, or the bottom must be above 90. Blood pressure is measured in mm Hg. Ask the prescriber to check your diagnosis and readings.

A BMI at or above 27 requires one or more of these conditions: pre-diabetes, where blood sugar is higher than normal but has not reached the diabetes range; a previous heart attack; a previous stroke; or peripheral artery disease that causes symptoms. Peripheral artery disease affects blood flow through arteries away from the heart. Ask the prescriber to confirm the exact diagnosis.

Your plan must either be a stand-alone Part D drug plan or provide drug coverage through a Medicare Advantage coordinated care plan. For some other kinds of plan, having a stand-alone Part D plan as well is required to qualify. Ask your plan to check its type against the Bridge rules.

A Part D payment in 2026 for any of these medicines on your behalf rules out using the Bridge in 2026. The rules checked September 26, 2026, had not yet set that test for 2027.

This programme excludes anyone with type 2 diabetes. Care for that use is handled through the ordinary Part D benefit.

Moderate to severe obstructive sleep apnea also rules out the Bridge. With this condition, breathing stops again and again during sleep.

A further exclusion concerns the liver disease MASH: scarring must be moderate to advanced, and cirrhosis must be absent. MASH means liver inflammation linked to fat buildup; cirrhosis is severe liver scarring. These medical uses go through Part D. Fatty liver alone does not establish this exclusion; ask the prescriber to check the exact condition.

A prescription and prior authorisation, meaning advance approval for payment, are required. The medicine must be prescribed alongside an ongoing programme of nutrition and physical activity.

As of September 26, 2026, the Bridge covered Foundayo (orforglipron) tablets, Wegovy (semaglutide) injections and tablets, and Zepbound (tirzepatide) in the KwikPen device. Zepbound single-dose pens and vials were excluded. Ask the pharmacy to confirm the exact product and device.

Check the programme’s money limits too

Covered drugs under Part D have a yearly cap on the amount you pay yourself. The Bridge’s $50 payments were excluded from that limit on September 26, 2026. Paying the Bridge bill therefore did not bring you closer to reaching the limit for your other Part D drug bills.

It offered no extra help with the bill for people on low incomes. Coupons could not be used for Bridge claims.

For other insurance, ask for the covered-drug list and your expected share. Ask what records the prescriber must send.